Indivior and Addex Enter Collaboration to Study Addiction
Thursday, January 4, 2018
Indivior UK Limited has entered a strategic collaboration with Addex Pharma S.A., a wholly-owned subsidiary of Addex Therapeutics Ltd. (SIX: ADXN), in the field of GABAB positive allosteric modulators (PAMs). GABAB PAMs have demonstrated preclinical efficacy and tolerability in animal models for alcohol use disorder (AUD) and cocaine use disorder (CUD)1,2. The collaboration includes an exclusive global license to lead candidate ADX71441, which is a novel, first-in-class, oral, small molecule and is expected to enter Phase 1 trials in 2018. The collaboration also includes exclusive global license to backup GABAB PAM compounds, as well as a research collaboration focused on discovering additional GABAB PAMs. The Addex GABAB program was recently awarded a $5.3 million grant by the National Institute on Drug Abuse ("NIDA") to support the development of ADX71441 in CUD3.
Under the terms of the agreement, Indivior is making an upfront payment to Addex of $5 million, and will also invest in research funding over the next two years to discover additional GABAB PAM compounds commercially-viable to treat addiction. Potential milestone payments to Addex could total $330 million over time if all development, regulatory and sales goals are achieved.
"As part of our leadership position in addiction, among the key priorities we are pursuing is continuing to review and invest in promising new treatments for this chronic and relapsing disease," said Shaun Thaxter, CEO of Indivior. "Modulation of the GABAB receptor pathway is an attractive mechanism, particularly for the potential it holds in advancing treatments for AUD and CUD. Further, we are excited about this new strategic collaboration with Addex to discover additional compounds targeting the GABAB receptor pathway, which will complement the current pipeline efforts we have underway to develop novel treatments for addiction."
"We believe Addex has the most advanced science in the area of GABAB allosteric modulation and look forward to rapidly advancing lead compound, ADX71441, into Phase 1 trials," said Christian Heidbreder, Chief Scientific Officer of Indivior. "As we continue to collaborate with the Addex team, we believe there is great potential for additional compounds to be discovered and developed related to this important mechanism for addiction science."